From the FY23 annual report:
They need to clear up specifically which organizations and channels are distributing the product to provide clarity to holders. The majority of the income earned in FY2023 circa $10M was generated solely in the US. However from reading FY2023 appears $300,000 was from product sales (down from previous year due to reduced CoviDx sales) however expected increase with marketing efforts in the US.
Worth noting, from what I could find, the estimated cost of Febridx as a unit is $24 AUD. Appears Henry Schein (European distributor) sells them at a pack of 25, so $600AUD per case.
From the FY23 annual report:They need to clear up specifically...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
2.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $19.46M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 151316 | 2.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.7¢ | 699854 | 3 |
View Market Depth
| Last trade - 08.47am 30/06/2025 (20 minute delay) ? |
| LDX (ASX) Chart |
Day chart unavailable